ClinicalTrials.gg
CompletedNCT02748863ALLUREUpdated Jul 15, 2019Results posted

Study of Secukinumab With 2 mL Pre-filled Syringes

A Phase 3 interventional study of Placebo and Secukinumab 2 mL form in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
15th of 54
214 · median 124
Started
2016
with 3 others
Phase 3
24 of 54
none open now
Registered
34th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 15th largest by enrollment, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 34th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.

Read the detailed description

This is a 52-weeks multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in 24 subjects with moderate to severe plaque-type psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • psoriasis
  • secukinumab
  • pre-filled syringes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for inclusion in this study must fulfill all of the following criteria:

  1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
  2. Men or women of at least 18 years of age at the time of Screening.
  3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
  4. Moderate to severe psoriasis as defined at Randomization by:

    • PASI score of 12 or greater, and
    • IGA mod 2011 score of 3 or greater (based on a scale of 0 - 4), and
    • Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
  5. Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by

    • Topical treatment and/or
    • Phototherapy and/or
    • Previous systemic therapy

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Randomization.
  2. Ongoing use of prohibited treatments. detailed in the protocol have to be adhered to. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited.

    Note: administration of 6 weeks prior to Randomization or during the study period is also prohibited.

  3. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
  4. Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  6. History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  7. History of to any of study drug constituent
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe

    Drug: Placebo

  • Experimental
    Secukinumab 2 mL form

    Secukinumab 300 mg, provided in a 2 mL pre-filled syringe

    Drug: Secukinumab 2 mL form

  • Active comparator
    Secukinumab 1 mL form

    Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)

    Drug: Secukinumab 1 mL form

Interventions

  • DrugPlacebo

    2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48

  • Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48

  • Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48

06

What researchers measure

Primary outcomes

  1. Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment

    Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: 12 weeks

  2. Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment

    The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline

    Time frame: 12 weeks

Secondary outcomes

  1. Participants With PASI 90 After 12 Weeks of Treatment

    Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline

    Time frame: 12 weeks

  2. Number of Participants With PASI 100 Response After 12 Weeks of Treatment

    Participants who achieved 100% reduction in PASI compared to baseline

    Time frame: 12 weeks

  3. Number of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response

    PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline

    Time frame: up to week 52

07

Results

Posted Jun 26, 2019
Limitations and caveats
"Other pre-specified outcomes" such as assess the subject usability and assessment of Dermatology Life Quality Index (DLQI) scores are exploratory in nature and are not reported in these results

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSecukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboSecukinumab 2 mL PFS Following PlaceboSecukinumab 2 x 1 mL PFS Following Placebo
Started72717100
Completed72696900
Not completed02200
Withdrew: Adverse event01000
Withdrew: Lack of efficacy00100
Withdrew: Withdrawal by subject01100
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSecukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboSecukinumab 2 mL PFS Following PlaceboSecukinumab 2 x 1 mL PFS Following Placebo
Started726903434
Completed676603233
Not completed53021
Withdrew: Lost to follow-up20000
Withdrew: Adverse event32020
Withdrew: Lack of efficacy01000
Withdrew: Pregnancy00001

Outcome measures

PrimaryParticipants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment

Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
12 weeks
Reported as:
Number · participants
Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment
participantsSecukinumab 2 mL PFSPlacebo
Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment641
Statistical analysis
  • Secukinumab 2 mL PFS vs Placebo · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 717.42 · 95% CI 68.00 to 7569.56
SecondaryParticipants With PASI 90 After 12 Weeks of Treatment

Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline

Time frame:
12 weeks
Reported as:
Number · participants
Participants With PASI 90 After 12 Weeks of Treatment
participantsSecukinumab 2 mL PFSPlacebo
Participants With PASI 90 After 12 Weeks of Treatment481
Statistical analysis
  • Secukinumab 2 mL PFS vs Placebo · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 168.39 · 95% CI 21.20 to 1337.22
SecondaryNumber of Participants With PASI 100 Response After 12 Weeks of Treatment

Participants who achieved 100% reduction in PASI compared to baseline

Time frame:
12 weeks
Reported as:
Number · participants
Number of Participants With PASI 100 Response After 12 Weeks of Treatment
participantsSecukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlacebo
Number of Participants With PASI 100 Response After 12 Weeks of Treatment28260
Statistical analysis
  • Secukinumab 2 mL PFS vs Placebo · t-test, 2 sided · p = < 0.0001 · Risk difference (rd): 38.75 · 95% CI 27.41 to 50.09
  • Secukinumab 2 x 1 mL PFS vs Placebo · t-test, 2 sided · p = < 0.0001 · Risk difference (rd): 36.48 · 95% CI 25.19 to 47.76
SecondaryNumber of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response

PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline

Time frame:
up to week 52
Reported as:
Number · participants
Number of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response
participantsSecukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboSecukinumab 2 mL PFS Following PlaceboSecukinumab 2 x 1 mL PFS Following Placebo
Week 1 IGA 0/110000
Week 1 PASI 5055101
Week 1 PASI 7502000
Week 1 PASI 9000000
Week 1 PASI 10000000
Week 2 IGA 0/121101
Week 2 PASI 501828110
Week 2 PASI 7545000
Week 2 PASI 9001000
Week 2 PASI 10001000
Week 3 IGA 0/1611101
Week 3 PASI 503940531
Week 3 PASI 751417000
Week 3 PASI 9044000
Week 3 PASI 10001000
Week 4 IGA 0/11923000
Week 4 PASI 505352651
Week 4 PASI 752932110
Week 4 PASI 901013000
Week 4 PASI 10033000
Week 8 IGA 0/14341000
Week 8 PASI 506660532
Week 8 PASI 755351000
Week 8 PASI 903531000
Week 8 PASI 100811000
Week 12 IGA 0/15549100
Week 12 PASI 506761522
Week 12 PASI 756458100
Week 12 PASI 904850100
Week 12 PASI 1002826000
Week 16 IGA 0/157520145
Week 16 PASI 50696102720
Week 16 PASI 75656001713
Week 16 PASI 905655084
Week 16 PASI 1003731051
Week 28 IGA 0/1645403025
Week 28 PASI 50716603330
Week 28 PASI 75696003228
Week 28 PASI 90625602621
Week 28 PASI 100443401612
Week 40 IGA 0/1605502825
Week 40 PASI 50696703333
Week 40 PASI 75666303131
Week 40 PASI 90585702724
Week 40 PASI 100403702017
Week 52 IGA 0/1555502826
Week 52 PASI 50676703132
Week 52 PASI 75636203031
Week 52 PASI 90545802526
Week 52 PASI 100403702016
PrimaryParticipants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment

The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline

Time frame:
12 weeks
Reported as:
Number · participants
Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment
participantsSecukinumab 2 mL PFSPlacebo
Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment551
Statistical analysis
  • Secukinumab 2 mL PFS vs Placebo · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 400.58 · 95% CI 47.48 to 3379.99

Adverse events

Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg (2mL PFS)0/72 (0%)0/72 (0%)33/72 (45.8%)
AIN457 300 mg (2x1mL PFS)0/71 (0%)1/71 (1.4%)39/71 (54.9%)
Placebo0/71 (0%)2/71 (2.8%)29/71 (40.8%)
Any AIN457 300 mg (2mL PFS)0/106 (0%)8/106 (7.5%)60/106 (56.6%)
Any Secukuinumab 300 mg (2x1mL PFS)0/105 (0%)5/105 (4.8%)68/105 (64.8%)
Any Secukinumab 300 mg0/211 (0%)13/211 (6.2%)128/211 (60.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSecukinumab 300 mg (2mL PFS)AIN457 300 mg (2x1mL PFS)PlaceboAny AIN457 300 mg (2mL PFS)Any Secukuinumab 300 mg (2x1mL PFS)Any Secukinumab 300 mg
Colitis ulcerativeGastrointestinal disorders0/721/710/711/1061/1052/211
Fibula fractureInjury, poisoning and procedural complications0/720/711/710/1060/1050/211
Diabetic ketoacidosisMetabolism and nutrition disorders0/720/711/710/1060/1050/211
Myocardial infarctionCardiac disorders0/720/710/710/1061/1051/211
Pancreatitis acuteGastrointestinal disorders0/720/710/710/1061/1051/211
Pharyngitis bacterialInfections and infestations0/720/710/710/1061/1051/211
Rib fractureInjury, poisoning and procedural complications0/720/710/710/1061/1051/211
HaemothoraxRespiratory, thoracic and mediastinal disorders0/720/710/710/1061/1051/211
HypoventilationRespiratory, thoracic and mediastinal disorders0/720/710/710/1061/1051/211
Pleural effusionRespiratory, thoracic and mediastinal disorders0/720/710/710/1061/1051/211
Most frequent other events
Showing 10 of 40
Most frequent other events
EventSecukinumab 300 mg (2mL PFS)AIN457 300 mg (2x1mL PFS)PlaceboAny AIN457 300 mg (2mL PFS)Any Secukuinumab 300 mg (2x1mL PFS)Any Secukinumab 300 mg
NasopharyngitisInfections and infestations7/728/718/7113/10617/10530/211
HeadacheNervous system disorders6/726/713/7110/1068/10518/211
PruritusSkin and subcutaneous tissue disorders5/723/713/7110/1064/10514/211
InfluenzaInfections and infestations0/721/710/712/1068/10510/211
DiarrhoeaGastrointestinal disorders2/723/710/716/1066/10512/211
FatigueGeneral disorders2/720/711/716/1063/1059/211
Back painMusculoskeletal and connective tissue disorders4/723/712/716/1064/10510/211
Respiratory tract infection viralInfections and infestations2/720/711/712/1065/1057/211
RhinitisInfections and infestations1/721/711/714/1065/1059/211
Upper respiratory tract infectionInfections and infestations1/721/712/715/1065/10510/211

Baseline characteristics

Age, Customized
Age, Customized(Participants)Secukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboTotal
<65 years686468200
>=65 years47314
>=75 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboTotal
Female28282581
Male444346133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 2 mL PFSSecukinumab 2 x 1 mL PFSPlaceboTotal
Caucasian646466194
Black2114
Asian44412
Pacific Islander0101
Other2103
08

Study locations

52 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85032, United States
  • Novartis Investigative Site
    Fountain Valley, California 92708, United States
  • Novartis Investigative Site
    Fremont, California 95438, United States
  • Novartis Investigative Site
    Miami, Florida 33155, United States
  • Novartis Investigative Site
    Marietta, Georgia 30060, United States
  • Novartis Investigative Site
    Savannah, Georgia 31406, United States
  • Novartis Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Novartis Investigative Site
    Verona, New Jersey 07044, United States
  • Novartis Investigative Site
    Portland, Oregon 97210, United States
  • Novartis Investigative Site
    Portland, Oregon 97223, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    San Antonio, Texas 78218, United States
  • Novartis Investigative Site
    Sugar Land, Texas 77479, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Novartis Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Novartis Investigative Site
    Berlin, 10629, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Muenchen, 80337, Germany
  • Novartis Investigative Site
    Kopavogur, 201, Iceland
  • Novartis Investigative Site
    Daugavpils, LVA LV-5404, Latvia
  • Novartis Investigative Site
    Jelgava, LVA LV-3001, Latvia
  • Novartis Investigative Site
    Riga, LVA LV-1003, Latvia
  • Novartis Investigative Site
    Ventspils, LVA LV-3601, Latvia
  • Novartis Investigative Site
    Riga, 1012, Latvia
  • Novartis Investigative Site
    Riga, LV-1001, Latvia
  • Novartis Investigative Site
    Olsztyn, 10-045, Poland
  • Novartis Investigative Site
    Warszawa, 02-507, Poland
  • Novartis Investigative Site
    Chelyabinsk, 454092, Russian Federation
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 107076, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191123, Russian Federation
  • Novartis Investigative Site
    Saint-Petersburg, 194021, Russian Federation
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Sant Joan Despi, Barcelona 08970, Spain
  • Novartis Investigative Site
    Bilbao, Bizkaia 48013, Spain
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Pontevedra, 36003, Spain
  • Novartis Investigative Site
    Bursa, 16059, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Dudley, West Midlands DY1 2HQ, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB7 5JD, United Kingdom
  • Novartis Investigative Site
    Dundee, DD1 9SY, United Kingdom
  • Novartis Investigative Site
    Surrey, RH1 5RH, United Kingdom
09

References and documents

Publications

  • Sigurgeirsson B, Schakel K, Hong CH, Effendy I, Placek W, Rich P, Keefe D, Bruin G, Charef P, Fu R, Hampele I, Patekar M. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. J Dermatolog Treat. 2022 May;33(3):1718-1726. doi: 10.1080/09546634.2021.1902925. Epub 2021 Apr 26. PubMed 33896356 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Aug 2017, 7 months.

Results were first posted in Jun 2019, 1 year 10 months after primary completion. A results delay was requested in Jul 2018.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2016
First posted
Apr 22, 2016
StartActual
Dec 12, 2016
Primary completionActual
Aug 8, 2017
CompletionActual
Jun 8, 2018
Results delay requested
Jul 16, 2018
Results first posted
Jun 26, 2019
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02748863
Responsible party
Sponsor
First posted
Apr 22, 2016
Start date
Dec 12, 2016
Primary completion
Aug 8, 2017
Completion
Jun 8, 2018
Results posted
Jun 26, 2019
Last update
Jul 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion